NMDA receptor modulators - Cadent Therapeutics/Novartis

Drug Profile

NMDA receptor modulators - Cadent Therapeutics/Novartis

Latest Information Update: 30 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cadent Therapeutics; Jubilant Biosys
  • Developer Novartis
  • Class Antidepressants; Small molecules
  • Mechanism of Action NR2B N-Methyl D-Aspartate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Depressive disorders

Most Recent Events

  • 17 Oct 2017 Luc Therapeutics is now called Cadent Therapeutics
  • 17 Oct 2017 Phase-I clinical trials in Depressive disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top